The 10% product revenue decline and widening net loss are the headline numbers — the stock will likely trade down on the miss vs consensus. However, the zoci pipeline data (62.5% iORR) and KarXT launch catalyst provide a floor. Watch for: (1) ZEJULA stabilization trajectory, (2) KarXT launch metrics in Q2, (3) TIVDAK NMPA decision timeline, and (4) zoci registrational study enrollment updates. The $761M cash runway supports the pipeline thesis but the commercial headwinds are real.
Price Chart
Executive Summary
Zai Lab reported Q1 2026 total revenue of $99.6M, down 6% YoY from $106.5M, and product revenue of $95.6M, down 10% YoY. Net loss widened to $51.0M ($0.05 per share) from $48.4M ($0.04 per share) in Q1 2025, driven by lower ZEJULA sales due to generic competition and higher R&D spend. The decline in headline revenue and widening loss is partially offset by strong pipeline progress (zoci AACR data, KarXT launch prep, positive partner readouts for povetacicept and elegrobart), but the near-term financial trajectory is negative.
Key Financial Metrics
Key Facts
- Total revenue $99.6M in Q1 2026, down 6% YoY from $106.5M
- Product revenue $95.6M, down 10% YoY (12% at CER)
- ZEJULA sales fell to $30.0M from $49.5M (-39% YoY) due to generic olaparib competition
- Net loss widened to $51.0M ($0.05 per share) from $48.4M ($0.04 per share)
- R&D expenses increased to $65.6M from $60.7M (+8% YoY)
- Cash and investments totaled $761.3M, down from $789.6M at year-end 2025
- XACDURO grew to $8.6M from $1.1M (+682% YoY); NUZYRA grew to $16.3M from $15.1M (+8% YoY)
- zoci showed 62.5% intracranial ORR at AACR; collaborations with Amgen and Boehringer Ingelheim announced
- KarXT launch preparations underway in China; TIVDAK under NMPA review
- Positive Phase 3 readouts for partner programs povetacicept (IgAN) and elegrobart (TED)
Financial Impact
Revenue decline of $6.9M YoY; net loss increase of $2.6M YoY; ZEJULA franchise decline of $19.5M YoY
Risk Factors
- ZEJULA erosion accelerating from generic olaparib VBP in China
- VYVGART NRDL pricing adjustment may continue to pressure sales
- KarXT launch execution risk in China
- R&D spend increasing without near-term revenue offset
- Cash burn rate of ~$28M/quarter may accelerate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031624 |
| Document: zlab-20260507.htm | 0001628280-26-031624 |
| Document: 0001628280-26-031624-index-headers.html | 0001628280-26-031624 |
| Document: 0001628280-26-031624-index.html | 0001628280-26-031624 |
| Document: 0001628280-26-031624.txt | 0001628280-26-031624 |
| 8-K Data (Synthetic) | 0001628280-26-031624 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Insider Cluster | $26.01 $26.08 | ▲ +0.27% | ▼ −0.20% | $24.33 (−6.46%) |
Aug 13, 2026 7w ago | Insider Cluster | $26.03 $26.02 | ▼ −0.04% | ▲ +1.93% | $24.33 (−6.53%) |
Aug 13, 2026 7w ago | Insider Cluster | $26.03 $26.02 | ▼ −0.04% | ▲ +1.93% | $24.33 (−6.53%) |
Aug 12, 2026 7w ago | 144 | $25.49 $26.72 | ▲ +4.83% | ▲ +5.27% | $24.33 (−4.55%) |
Jul 1, 2026 13w ago | Insider Cluster | $19.15 $19.35 | ▲ +1.04% | ▲ +0.78% | $24.33 (+27.05%) |
Jun 29, 2026 13w ago | Insider Cluster | $19.00 $19.08 | ▲ +0.42% | ▼ −0.18% | $24.33 (+28.05%) |
Jun 11, 2026 16w ago | Institutional Cluster | $17.64 $17.88 | ▼ −1.36% | ▼ −0.93% | $24.33 (−37.93%) |
May 21, 2026 19w ago | 8-K | $18.61 $17.09 | ▼ −8.17% | ▼ −9.83% | $24.33 (+30.74%) |
May 19, 2026 19w ago | Insider Cluster | $18.81 $18.69 | ▼ −0.64% | ▼ −1.88% | $24.33 (+29.35%) |
May 19, 2026 19w ago | Insider Cluster | $18.81 $18.69 | ▲ +0.64% | ▲ +1.88% | $24.33 (−29.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access